

Ð

01

on

01

*****=



ERNs and Research: State of play from the European Commission perspective

Iiro Eerola, DG RTD Hélène Le Borgne, DG SANTE Anneli Torronnen, DG SANTE European Commission

Health and Food Safetv



Food Safetv



European Reference Networks (ERNs)

- 1) Background and recent history of ERNs
- 2) ERNs and Research from DG SANTE perspective
- 3) ERNs and medicinal product authorisation point of view
- 4) ERNs and Research from DG RTD perspective







The context: Healthcare in the EU

- National competences and systems (28 so far):
 - Different rights and entitlements
 - Different organisational models
 - Beveridge (Public national healthcare systems) vs Bismarck (social security based models) and mixed models
- Subsidiarity principle
- Healthcare collaboration based on voluntary participation
- **Cross-border healthcare directive** (only legislation addressing healthcare at EU level) to facilitate mobility of patients across borders and to strength cooperation and added value

Food Safetv







The European Reference Networks (ERNs)

Networks of healthcare providers aiming at **improving quality**, and safety and access to highly specialised healthcare


Patients affected by rare or low prevalence and complex diseases

Multidisciplinary approach (different specialities/areas of knowledge) Added value at EU level

Need of cooperation: •Scarcity knowledge •Need education •Complexity / high cost

•Effectiveness in the use of resources

Health and Food Safety



The rationale behind

- Many of those affected by a rare or complex condition do not have access to diagnosis and high-quality treatment.
- Expertise and specialist knowledge may be scarce because patient numbers are low
- No country alone has the knowledge and capacity to treat all rare and complex diseases.
- Important delay in diagnosis because lack of knowledge or right referal systems
- Lack of diagnostic capacity (no tests available) and treatments in many cases












Networking is the basis: **"The knowledge travels, not the patient"**

- Exchange of expertise and clinical data on patient cases through the network and across the EU
- Swift and smooth **contact between providers** and between patients and providers at a distance
- Collaborative/cooperative actions and systems
- Networking activities, specific network tools and IT solutions















Health and Food Safety








Telemedicine and other IT solutions and tools



Outcome call 2016







AWARD CEREMONY 3rd European Reference Networks Conference 9 March 2017 - Vilnius, Lithuania



The 24 Networks approved







European Commission

		ERN EuroBloodNet	Onco-Hematological Diseases
ERN BOND	Bone Diseases		
		ERN EURO-NMD	Neuromuscular Diseases
ERN CRANIO	Craniofacial anomalies and ENT		
	disorders	ERN GUARD-HEART	Diseases of the Heart
Endo-ERN	Endocrine Conditions	ERN ITHACA	Congenital Malformations and
ERN EpiCARE	Rare and Complex Epilepsies		Intellectual Disability
-		MetabERN	Hereditary metabolic diseases
ERKNet	Kidney Diseases		
		ERN PaedCan	Paediatric Cancer
ERN GENTURIS	Genetic Tumour Risk Syndromes	ERN RARE-LIVER	Hepatological Diseases
ERN-EYE	Eye Diseases		
	-	ERN ReCONNET	Connective Tissue and
ERNICA	Inherited and congenital anomalies		Musculoskeletal Diseases
		ERN RITA	Immunodeficiency, AutoInflammatory
ERN-LUNG	Respiratory Diseases		and Auto Immune Diseases
ERN-RND	Neurological Diseases	ERN TRANSPLANT-	Transplantation in Children
		CHILD	
ERN-Skin	Skin Disorders	VASCERN	Multisystemic Vascular Diseases
ERN EURACAN	Solid Adult Cancers	ERN eUROGEN	Urogenital Diseases



Phases of the ERN life cycle





We are hero

2011-14

Legislation and initial planning

Directive

Implementing decisions

Awareness and communication

2015-16

Implementation: (Approval stage)

Design and development Assessment tools

Call for ERN

Assessment of Network proposals

Approval of ERNs

project cycle re-initiation



2017-18

Implementation: (deployment stage)

Establishment

Initial organisational phase

Functioning (initial actions and services)

Partial service production

2019-20

Consolidation


Full service production Continuous monitoring Performance indicators and initial outcome assessment

Health and Food Safetv

Actors involved in the ERN implementation







ERN's IT Platform & tools





Com Web/video conferencing, Virtual clinical meetings **CLINICAL** Exchange of Images (Radiology), patient diagnostic tests & pictures (genetics, management pathology etc., (PACS) System (CPMS) Exchange of clinical information and patient data Communication Management / governance tools **IT** tools and collaboration Communication / conferencing tools

Other modules

eTraining / eLearning

Public webpage / ERNs webs

Health and Food Safetv

Funding / support









THE THIRD HEALTH PROGRAMME 2014-2020 FUNDING HEALTH INITIATIVES









EUROPEAN UNION STRUCTURAL FUNDS







Research, innovation & knowledge generation Key Elements of ERNs

A framework for structured cooperation to maximise cross-country expertise through joint research projects and clinical trials



ERN provide an opportunity to build top level translational and basic research around shared strategies

Dissemination of research results, education & training activities





> ERNs shall have at least 3 of the following objectives:

 (a) to help realise the potential of European cooperation regarding highly specialised healthcare for patients and for healthcare systems by **exploiting innovations** in medical science and health technologies;

> (b) to contribute to the **pooling of knowledge** regarding sickness prevention;

 \succ (c) to facilitate **improvements in diagnosis** and the delivery of high-quality,

accessible and cost-effective healthcare for all patients with a medical condition requiring a particular concentration of expertise in medical domains where expertise is rare;

➤ (d) to maximise the cost-effective use of resources by concentrating them where appropriate;

(e) to reinforce <u>research</u>, epidemiological surveillance like registries and provide training for health professionals;

(f) to facilitate mobility of expertise, virtually or physically, and to develop, share and spread information, knowledge and best practice and to foster develop-ments of the diagnosis and treatment of rare diseases, within and outside the networks;
 (g) to encourage the development of quality and safety benchmarks and to help develop and spread best practice within and outside the network;

> (h) to help Member States with an insufficient number of patients with a particular medical condition or lacking technology or expertise to provide highly specialised services of high quality.



Registries, research and ERNs



Commission





Patient Data

Population Cohorts / Concentration of cases Secured Databases Clinical / Imaging / Biological Data Genetics, Molecular Pathology

IT Solutions / Communication between HCP

common elements , principles and requisites

Health and Food Safety





Towards collaborative efforts of ERNs in the area of Research

• Explore... interaction with EMA and clinical trials related initiatives, IMI initiatives, etc.

• But also potential and interest in non-commercial research projects (for example on effectiveness of treatments, impact of guidelines etc.)

BUT first of all:

• Start by mapping and building up research capabilities among ERNs:

- Internally to each of the 24 ERNs
- As group of ERNs

Health and Food Safetv





European

Building up research capabilities among ERNs (1)

Health and

Food Safetv

• Within each ERN:

- Thematic groups in terms of diseases,
- Transversal Working Groups on Research (and/or Registries)
- For a coordinated approach within the ERN

(building upon strengths and needs of all ERN members from that ERN – it could start by a mapping exercise...)

The European Rare Kidney Disease	Reference Networks		
Home Our Experts - Disease Information Virtu	ual Consultation Guidelines & Pathways - Registries -	Education & Training + Research + The ERNs	
Current research projects			
Clinical Trials	Cohort Studies and Registries	Translational Research Projects	
Glomerulopathies	Glomerulopathies	Glomerulopathies	
MESNEPH Study	• ERK-REG	Study of the pathogenetic mechanisms underlying	
A randomized, double-blind, placebo-controlled phase study to evaluate the safety and efficacy of twoscare (COV/COV) is patients with CO	 Management of children with congenital nephrotic syndrome 	post-transplant disease recurrence in patients with idiopathic focal segmental glomerulosclerosis (PARSEC study)	
Avacopan (CCX168) in patients with C3 glomerulopathy (CL011_168 trial)	Identification of new genes associated to steroid resistant nephrotic syndrome (SRNS study) PodoNet SRNS Registry Complement abnormatilies in primary membranoproliferative glomerulonephritis/C3G Tubulopathies and metabolic disorders FRK-REG	 Predicting responsiveness to steroid therapy in nephrotic syndrome (PRESTINS) 	
 A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE-inhibition therapy on glomerular proliferative lesions in patients with extracapillary element developing (CTDA to trich). 		Elucidating the genetic pathomechanism underlying rare and hereditary tichery diseases (RND) Uriang Elomaters: Analysis of Urine in patients with tubular and giomerular kidney disease Urubulopathiles and metabolic disorders	
glomerulonephritis (EXTRA study) • Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome			
Randomized clinical trial to establish optimal prednisone therapy in children with steroid-sensitive nephrotic syndrome	Thrombotic microangiopathies • ERK-REG	Elucidating the genetic pathomechanism underlying rare and hereditary kidney diseases (RKD) Protection from reactive metabolites in CKD and diabetes	
The PREDNOS 2 Study	 Genetic and biochemical abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura (HUS-TTP study) 	Urinary Biomarkers: Analysis of Urine in patients with	
Thrombotic microangiopathies		tubular and glomerular kidney disease	
 Single arm study of ALXN1210 in complement inhibitor treatment-naive adult and adolescent patients with 	Structural Kidney Disorders	Thrombotic microangiopathies	
athypical Hemolytic Uremic Syndrome (ALXN1210- aHUS-311 trial)	ADPedKD	Elucidating the genetic pathomechanism underlying rare and hereditary kidney diseases (RKD)	
A phase 2, uncontrolled, three-stage, dose-escalation cohort study to evaluate the safety, pharmacokinetics,	 NEOCYST (Network of Early Onset CYSTic kidney diseases) 	 Urinary Biomarkers: Analysis of Urine in patients with tubular and glomerular kidney disease 	
pharmacodynamics, immunogenicity, and clinical activity of OMS721 in adults with thrombotic	ADPKD Tolvaptan Treatment Registry - AD(H)PKD	Structural Kidney Disorders	
microangiopathies (OMS-721-TMA-001 trial)	ARegPKD	ANTENATAL - Multicenter Validation of a Fetal urine	
Structural Kidney Disorders	CKD and Dialysis in Children	Peptidome-based Classifier to Predict Post-Natal Renal Function in Posterior Urethral Valves	
PREDICT – Antibiotic Prophylaxis and Renal Damage Damage	• ERK-REG	A novel approach to understand the molecular	
in Congenital Abnormalities of the Kidney and Urinary Tract	 Population pharmacokinetic-pharmacodynamic (PK- PD) modelling of colecalciferol in children 	mechanisms causing structural kidney malformations in human	

· Cardiovascular and bone health in children and young

Assessing calcium balance in children with chronic

kidney disease to optimise treatment strategies

CKD and Dialvsis in Children

EDKNAt

```
    International Adapted PD Proof of Concent Study

Effects of Haemodiafiltration (HDF) vs Conventiona
  Haemodialysis (HD) on Growth and Cardiovascula
 Markers in Children - 3H (HDF, Hearts and Height)
 Study
```

```
    Remote patient monitoring (RPM) in children

undergoing peritoneal dialysis
```

adults with kidney failure

Renaltract Marie Curie International Training Network

The RENome and beyond

renal tract malformations

morphogenesis

· Using stem cell technologies to understand huma

Neocyst WP5: Epithelial function in cystic kidney

disease: defects of cell adhesion and epithelial





Building up research capabilities among ERNs (2)

- For the whole group of ERNs:
- Thanks to the <u>Working Group on Research</u> of the ERN <u>Coordinators' Group</u>

→ Different actions by different WG members since WG creation in 2017 (EJP, FP9, RD-ACTION Workshop with EMA...)
 → now moving towards a more coordinated approach, involving all WG members and supporting all ERNs

- With <u>RD-ACTION Workshop today</u>: survey on needs of ERNs regarding research (but views to be confirmed and consolidated)







Building up research capabilities among ERNs (3)

- For the whole group of ERNs:
- To be coordinated with the work of the <u>Working</u> <u>Group on Ethics</u> of the ERN Coordinators' Group

 \rightarrow for example in the area of cooperation with industry

!! WORK IN PROGRESS !!

- To be coordinated with the work of the ERN Board of Member States and with national policies



Board of Member States (BoMS) statement on ERNs & industry **■**



Commission

"In recognition of the importance of industry in improving our knowledge of rare conditions and developing clinical tools and therapies, **the Board of Member States agrees with engagement between ERN members and industry <u>where</u>** <u>appropriate, for example in clinical trials and</u> <u>research projects</u>. Board of Member States

On Reference

Statement on European Reference Networks (ERNs) and industry

November 2016

In recognition of the importance of industry in improving our knowledge of rare conditions and developing clinical tools and therapies, the Board of Member States agrees with engagement between ERN members and industry where appropriate, for example in clinical trials and research projects.

However, there is no legal provision for the involvement of external stakeholders, including industry, in the operation and governance of ERN. To address this issue and to steer ERN in their thinking on engagement with industry, the Board of Member States offers the following guidance:

Conducting some aspects of research and in particular clinical trials will be an integral task of ENts which may require collaboration with industry. This requires defining in advance the relations with industry so that they will be organised in an open and transparent manner. In particular, access to the data from registries and biobanks has to be carefully defined respecting the patients' rights and relevant national and European legislation.

A complete transparency policy should apply to the relationship between ERNs and industry

Industry stakeholders cannot have a place in the governance structure of an ERN.

 There must be no industry funding of any operational ERN activity (e.g. activities such as, but not exclusive to: the management and running of the network, meetings of the members, development of diagnostic guidelines etc.)

 Each designated ERN should establish a charter endorsed by all fts members, to define its own Conflict of Interest Policy and ensure disclosure of all financial and non-financial conflicts of interest before any engagement commences.

 Conflict of interest policy must respect relevant national and European legislation and follow the recommendations and guidelines developed by independent organisations and recognised bodies.

* Each Healthcare provider (HCP) must respect and follow the national legislation relating to conflict of interest.

However, there is no legal provision for the involvement of external stakeholders, including industry, in the operation and governance of ERN. To address this issue [...], the BoMS offers the following guidance:

* Conducting some aspects of research and in particular clinical trials will be an integral task of ERNs which may require collaboration with industry. This requires defining in advance the relations with industry so that they will be organised in an **open and transparent manner**. In particular, access to the data from registries and biobanks has to be carefully defined respecting the patients' rights and relevant national and European legislation.

* A **complete transparency policy** should apply to the relationship between ERNs and industry. [...]





[...]

* Industry stakeholders cannot have a place in the governance structure of an ERN.

* There must be **no industry funding of any operational ERN activity** (e.g. activities such as, but not exclusive to: the management and running of the network, meetings of the members, development of diagnostic guidelines etc.)

* Each designated ERN should establish a charter endorsed by all its members, to define its own Conflict of Interest Policy and ensure disclosure of all financial and non-financial conflicts of interest before any engagement commences.

[...] "

! More on this by Board representative later today !

Statement available at:

https://ec.europa.eu/health/sites/health/files/ern/docs/statement_industry_ conflictofinterest_en.pdf





Towards collaborative efforts of ERNs in the area of Research – at different levels:

ERN community:

- Within each ERN
- Coordinated approach for the whole ERN group, via the Working Group on Research and the ERN Coordinators' Group
- **Member States'** research agendas, Public Health policies, National plans on Rare Diseases etc. Citation: Clin Transl Sci (2018) 11, 21–27; doi:10.1111/cts.12500 o 2017 ASCPT. All rights reserved
- Other views:
 - Patients' organisations,
 - Professional associations (national, European, International)
 - Industry -
 - Other stakeholders e.g. IRDiRC -

REVIEW

Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective

Christopher P. Austin^{1,4}, Christine M. Cutillo¹, Lilian P.L. Luu², Anneliene H. Jonker², Ana Rath^{2,3}, Daria Julkowska⁴, David Thomson², Sharon F. Teny², Beatrico de Montleau¹, Diego Ardigo³, Virginie Hivref¹, Kurd M. Boycott¹, Gareth Baynam^{10,1} Petra Kuntmam¹, Domenica Taurusci², Manno Lochmille^{4,1}, Makota Suematu⁴, Catol no Beagha ^{10,1}, Gareth Baynam^{10,1} ne Norstedt¹⁶, Lu Wang¹⁸ and Hugh J.S. Dawkins¹⁹ on behalf of the International Rare Diseases Research Consortium (IRDiRC

The International Rare Diseases Research Consortium I ne international Nare Diseases Nesearon Consortium (IRDIRC) was founded in 2011 with the conviction that rare diseases research had reached a critical juncture. Proof of principle existed that rare diseases could be diagnosed, new treatments successfully developed and approved, and improvements in quality and quantity of life achieved. Goverment research funders, companies, scientists, and patient advocacy groups had all demonstrated their commitment and effectiveness in contributing to progress in rare diseases and effectiveness in contributing to progress in rare diseases research. However, the work was largely atomized, with each organization, each country, and the champions of each dis-ease pursuing independent, often duplicative solutions. The scale of the "rare disease problem" – thousands of rare dis-eases, the vast preponderance of them with no approved treatment, and decades-long diagnostic odysseys for many patients-led to the realization that the time had arrived for patients—ted to the realization that the time had arrived to global cooperation and collaboration among the many stake-holders active in rare diseases research, to capitalize on these proofs of principle, and maximize the output of rare diseases research efforts around the world. IRDIRC's initial aims were to aid in the achievement of two overarching objectives: to contribute to the development of 200 new therapies and the means to diagnose most rare diseases by the year 2020.¹ For more detailed information on the history, governance, and nascent stages of the Consortium, please refer to the accompanying piece on the first 6 years of IBDIRC². Due to the remarkable global surge in activity in rare dis-eases research over the last 6 years, including contributions by IRDIRC, the Consortium's 2020 goal for 200 new therapies was achieved in early 2017-3 years ahead of scheduleand the goal for diagnostics-the ability to diagnose most rare diseases by 2020-is within reach; these accomplish-ments were celebrated at the 3rd IRDIRC Conference in Paris

in February 2017.³ The 6 years preceding this 2017 con ference have been truly extraordinary for the rare diseases research community and for rare disease patients. Major public-sector research initiatives focused in this area have emerged or expanded in many countries, most notably from the US National Institutes of Health (NIH), the European Com mission (EC), and the newly formed Japan Agency for Med-ical Research and Development (AMED). Engagement and partnering among public funders, scientists, industry, and people living with rare diseases have gone from being the exception to commonplace. IBDiBC has been a major pos itive factor in raising public awareness about rare diseases, the need for more research to address them, and for collab-orative tools which allow ethical data sharing for and with patients. It has also clearly led to increased investment of public- and private-sector research funds for rare diseases in addition to the research funding raised by patients and patient organizations. IRDIRC has helped to catalyze several important initiatives that are improving collaboration among researchers and enhancing the ability of patients to engage as constructive partners in research.2,

As gratifying as these developments are, those who lead much of the global rare diseases research community are well aware of the enormous challenges that lie ahead for all patients living with rare diseases to receive an accurate and timely diagnosis, to have approved treatments available to get access to those treatments, and to realize improve ments in their quality and quantity of life; in short, to be able to live the best life possible. Although the means to diagnose most rare diseases that are caused by mutations in the coding genome is on track to be achieved either via genotype-phenotype correlation or novel gene discovery, in practice most patients with rare diseases spend years in the

Food Safetv





... for patients and professionals

- improve public and professional awareness of rare and complex diseases
- increase the likelihood of early and accurate diagnosis and effective treatment where available.
- platforms for the development of guidelines, training and knowledge-sharing.
- facilitate large clinical studies to improve understanding and develop new drugs
- An opportunity for networking with likeminded experts from across Europe — ending the professional isolation that many experts in rare diseases face.

ERNs offer the potential to give patients and doctors across the EU access to the best expertise and timely exchange of life-saving knowledge, without having to travel.







... for the Healthcare systems and society

✓ Innovation in healthcare delivery is the cornerstone of the ERN system

✓ Development of **new care models**, and innovative medical solutions and devices, changing the way in which treatment itself is delivered.

✓Incubators for the development of **digital services** for the provision of virtual healthcare.

✓Will help to **boost economies of scale** and ensure a more efficient use of resources, with a positive impact on the sustainability of national healthcare systems.

✓ The networks are a visible demonstration of what solidarity can achieve in Europe.





European Commission



Further information:



http://ec.europa.eu/health/ern/policy/index_en.htm

